FDA Breakthrough Therapy designation received for PF614-MPAR ~~ PF614-MPAR second clinical trial initiated ~~ Lead clinical candidate identified for OUD program ~~ PF614 Phase 3 trial poised to ...
Chronic pain is a condition that affects millions of people worldwide, and its management has been a significant challenge for medicine. As research progresses, important discoveri ...